Improving Care

Reducing morbidity and mortality and enhancing quality of life

Informing Policy

Transforming health care at the local, national and international levels

Featured Projects

With more than 80 scientists, research at Advancing Health encompasses a wide breadth of areas

COVID-19

The Evidence Speaks

A recurring feature highlighting the latest in Advancing Health research

Our People

In the News

Research Resources

From design to execution, Advancing Health provides a broad range of support services

Work in Progress Seminar Series

Kamran Shojania

SCIENTIST, MD, FRCPC

Dr. Kamran Shojania graduated with a MD from the University of British Columbia (UBC) in 1989.

Research Interests

  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Ankylosing spondylitis
  • Biologic therapies
  • Clinical trials

In 1993, he completed his specialty training in Internal Medicine at UBC and worked as Chief Medical Resident at Vancouver General Hospital.

He subsequently completed his fellowship in Rheumatology in June 1995 at UBC and was awarded a Canadian Arthritis Society scholarship in 1995.

Currently, Dr. Shojania is a Clinical Professor and Head of Rheumatology at UBC, where he also holds the position of Rheumatology Postgraduate Program Director. He was the Medical Director of the Vancouver Pain Clinic from 1996 to 2001. From 1998 to 2007, he was the Director of Continuing Medical Education in the UBC Division of Rheumatology, and from 2001 to 2006, he was the recipient of a Clinician-Teacher Award from The Arthritis Society. He is the 2003 recipient of the UBC Faculty of Medicine Award for Excellence in Teaching.

Dr. Shojania has been in rheumatology practice since 1995 and is on staff at St. Paul’s Hospital and Vancouver General Hospital. He is an investigator at Arthritis Research Canada (ARC) in Vancouver and from 2000 to 2006 he was the Director of Clinical Trials at the ARC. He is a founding member and former Director of the Canadian Rheumatology Research Consortium. He is involved in several ongoing clinical trials in the areas of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and ankylosing spondylitis.